Journal
NEUROBIOLOGY OF DISEASE
Volume 36, Issue 2, Pages 242-251Publisher
ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.nbd.2009.07.010
Keywords
Niemann-Pick disease type C; CNS inflammation; Non-steroidal anti-inflammatory drugs; NSAIDs; Miglustat
Categories
Funding
- National Niemann-Pick Disease Foundation (NNPDF)
- Niemann-Pick Disease Group (UK)
- Medical Research Council, UK
- Medical Research Council [G0700969] Funding Source: researchfish
- MRC [G0700969] Funding Source: UKRI
Ask authors/readers for more resources
Niemann-Pick disease type C1 (NPC1) is a neurodegenerative lysosomal disorder characterized by sphingolipid and cholesterol storage in the late endocytic system. In common with other neurodegenerative diseases, activation of the innate immune system occurs in the brain resulting in neuro-inflammation. Targeting inflammation in the brain therefore represents a potential clinical intervention strategy that aims to slow the rate of disease progression and improve quality of life. We evaluated non-steroidal anti-inflammatory drugs (NSAIDs) and an anti-oxidant to determine whether these agents are disease modifying in an acute mouse model of NPC1. NSAIDs significantly prolonged the lifespan of NPC1 mice and slowed the onset of clinical signs. However, anti-oxidant therapy was of no significant benefit. Combining NSAID therapy with substrate reduction therapy (SRT) resulted in additive benefit These data suggest that anti-inflammatory therapy may be a useful adjunctive treatment in the clinical management of NPC1, alone or combined with SRT. (C) 2009 Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available